Clinical TrialsCLYM received FDA clearance for the Ph2 pMN study, supported by encouraging early Ph1b data that showed promising B cell depletion, complete remission, sustained clinical benefits, and a favorable safety profile.
Drug DevelopmentClimb Bio's lead drug budoprutug, a monoclonal antibody targeting CD19, has potential across a wide range of immune-mediated diseases.
Financial StabilityThe company ended with significant cash reserves, sufficient to fund operations through 2027, providing financial stability.